Michael R. Harrison

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

Robert J. Motzer, Brian I. Rini, David F. McDermott et al. · Journal of Clinical Oncology · 2014 · 1.1K citations · Full text

Medicine, Immunology, Oncology +17

10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial

Alison Halliday, Michael R. Harrison, Elizabeth Hayter et al. · The Lancet · 2010 · 925 citations · Full text

Medicine, Neurosurgery, Surgery +16

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

Robert J. Motzer, Brian I. Rini, David F. McDermott et al. · The Lancet Oncology · 2019 · 780 citations · Full text

Medicine, Oncology, Pharmacology +12

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 648 citations · Full text

Medicine, Oncology, Pharmacology +11

Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal et al. · Journal of the National Comprehensive Cancer Network · 2017 · 580 citations · Full text

Medicine, Oncology, Radiation Oncology +16